Product Description
Troglitazone decreases insulin resistance (improves insulin sensitivity), which results in reduced plasma glucose and insulin levels in patients with non-insulin-dependent diabetes mellitus (NIDDM). Risk factors for cardiovascular disease such as elevated proinsulin and triglyceride levels are also reduced by troglitazone (Sourced from: https://pubmed.ncbi.nlm.nih.gov/9211083/)
Mechanisms of Action: PPAR-g Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: Bangladesh | Chile | New Zealand | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Parke-Davis
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Atherosclerosis
Phase 2: Liposarcoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| P30CA006516 | P2 |
Completed |
Liposarcoma |
2000-01-01 |
2019-03-21 |
Treatments |
|
| AG0028 | P3 |
Completed |
Atherosclerosis |
2000-04-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/12/2023 |
News Article |
Presales Software Market Forecast Report 2023-2030 |
|
01/05/2023 |
News Article |
Tissue Dynamics Unveiling DynamiX® a Bionic Multi Organ-on-Chip Bioanalyzer |
|
10/05/2021 |
News Article |
EmphyCorp Inc. Non-Steroidal N115 Nasal Spray Completed Phase III Clinical Trial for COVID-19, Long COVID-19 (Long Haulers), and Pulmonary Fibrosis |
|
05/18/2021 |
News Article |
NDA Partners Appoints Michael A. Eldon, PhD, FCP as Partner in the Firm |